|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C26H30N6O3 |
|||
| Molecular Weight | 474.55 | CAS No. | 1234480-50-2 | |
| Solubility (25°C)* | In vitro | DMSO | 80 mg/mL (168.58 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | XMD8-92 is a potent and selective dual inhibitor of big map kinase (BMK1, ERK5) and bromodomain-containing proteins (BRDs, BET) with Kd of 80 nM and 170 nM for ERK5 and BRD4(1), respectively. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro | XMD8-92, via inhibition of BMK1 activation, significantly induces p21 expression in cells, and mediates suppression of cancer cell proliferation. [1] XMD8-92 markedly abrogates the inhibitive effects of hydroxysafflor yellow A (HSYA) on hepatic stellate cell (HSC) activation, and blockes the HSYA-mediated MEF2C down-regulation. [2] |
||||
| In vivo | XMD8-92 (50 mg/kg i.p.) significantly inhibit the growth of the xenografted human or syngeneic mouse tumors by blocking tumor cell proliferation and tumor-associated angiogenesis. [1] XMD8-92 inhibits pancreatic tumor xenograft growth by significant downregulation of DCLK1 and several of its downstream targets. [3] |
Protocol (from reference)
| Animal Study: |
|
|---|
References
Customer Product Validation
-
, , Int J Oncol, 2017, 51(1):91-103
-
Data from [Data independently produced by , , Oncotarget, 2014, 5(10): 3145-58]
-
Data from [Data independently produced by , , J Cell Physiol, 2014, 229(7): 856-67]
-
Data from [Data independently produced by , , PLoS One, 2015, 10(4):e0125054]
Selleck's XMD8-92 has been cited by 33 publications
| Protective effects of macrophage-specific integrin α5 in myocardial infarction are associated with accentuated angiogenesis [ Nat Commun, 2023, 10.1038/s41467-023-43369-x] | PubMed: 37985764 |
| Extracellular signal-Regulated Kinase 5 (ERK5) is required for the Yes-associated protein (YAP) co-transcriptional activity [ Cell Death Dis, 2023, 14(1):32] | PubMed: 36650140 |
| Extracellular signal-Regulated Kinase 5 (ERK5) is required for the Yes-associated protein (YAP) co-transcriptional activity [ Cell Death Dis, 2023, 14(1):32] | PubMed: 36650140 |
| Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition [ Front Cardiovasc Med, 2023, 10:1187490] | PubMed: 37711550 |
| Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition [ Front Cardiovasc Med, 2023, 10:1187490] | PubMed: 37711550 |
| Identification of a Novel ERK5 (MAPK7) Inhibitor, MHJ-627, and Verification of Its Potent Anticancer Efficacy in Cervical Cancer HeLa Cells [ Curr Issues Mol Biol, 2023, 45(7):6154-6169] | PubMed: 37504304 |
| Glucose Starvation or Pyruvate Dehydrogenase Activation Induce a Broad, ERK5-Mediated, Metabolic Remodeling Leading to Fatty Acid Oxidation [ Cells, 2022, 11(9)1392] | PubMed: 35563698 |
| ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology [ Cancers (Basel), 2022, 14(14)3509] | PubMed: 35884568 |
| Establishment and characterization of immortalized sweat gland myoepithelial cells [ Sci Rep, 2022, 12(1):7] | PubMed: 34997030 |
| Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5/Mer signaling pathway [ FEBS Open Bio, 2022, 12(8):1498-1508] | PubMed: 35778889 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.